XENEXenon Pharmaceuticals Inc.
Pharmaceutical Preparations
- Revenue
- $8M
- Operating margin
- -4974.3%
- EBITDA
- −$371M
- 34% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- −$109M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired716% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $18M | $9M | $0 | $0 | $8M | |
| Operating income | −$79M | −$129M | −$214M | −$279M | −$373M | 34% |
| Net income | −$79M | −$125M | −$182M | −$234M | −$346M | 48% |
| Operating cash flow | −$70M | −$101M | −$151M | −$181M | −$279M | 54% |
| Capex | $2M | $3M | $6M | $3M | $799K | 74% |
| Stock-based comp | $10M | $20M | $32M | $51M | $54M | 5.9% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $2M · 2
- Open-market sells, 12 mo
- $0 · 0
- Net
- $2M
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | — | — | 291 | 120 |
| FY2024 | — | — | 255 | 91 |
| FY2023 | — | — | 299 | 92 |
| FY2022 | — | — | 256 | 89 |
| FY2021 | — | — | 203 | 99 |